Board of Directors
Frank joined Ampersand Capital as an Operating Partner in 2016, and serves as Chairman of Gyros Protein Technologies. Frank most recently served as CEO of Affymetrix, a leading provider of genomics and cell biology products that was sold in 2016 for $1.3 billion. Previously, Frank was CEO of Dionex, a leading provider of analytical instrumentation that was sold in 2011 for $2.1 billion. He also held senior executive positions at Perkin Elmer, Packard Bioscience and Bio-Rad Laboratories. Frank holds a Ph.D. in molecular and cellular biology from Indiana University.
Eric Lev is currently a Partner at Ampersand Capital. Eric, who joined Ampersand in 2013, has 15 years of middle market healthcare investment experience. His board seats have included CutisPharma, Genoptix, LakePharma and Nexcelom. Most recently he spent seven years as a member of the investment team at Water Street Healthcare Partners. Prior to Water Street, Eric worked at Beckman Coulter and at One Equity Partners. Eric holds a B.A. in Economics from Northwestern University and a M.B.A. from the University of Chicago.
Dr. David A. Smoller served CEO of Sage Labs, a Life Science CRO based on Gene Editing technology until acquired By Horizon Discovery ( HZD.L) David continued at Horizon as Chief Business Officer and Board Member until December of 2015. Previous to those roles, Dr. Smoller was the Chief Scientific Officer of Sigma-Aldrich Corporation since February 2011 until August 3, 2012. Dr. Smoller served as the President of Research Biotech Business Unit of Sigma-Aldrich Corp. since July 5, 2007 and served as its Vice President of Research and Development since June 1, 2004.
Dr. Smoller served as President and Chief Executive Officer of ProteoPlex, a seed stage spinout focusing on functional genomics. He founded ProteoPlex in 2001 and led the St. Louis-based company through its product development and final acquisition by Merck KgA. In 1992, Dr. Smoller founded Genome Systems Inc., in St. Louis, which provided the scientific community with access to genome project-related technologies. Dr. Smoller stayed at the helm of Genome Systems, Inc. until it was acquired in 1996 by the Incyte Corporation. Dr. Smoller joined Incyte as Vice President eventually becoming Senior Vice President, overseeing the Global Genomics, Business Unit.
Dr. Smoller earned a doctorate degree in Molecular Biology and a bachelor’s degree in Biology from Emory University in Atlanta, Georgia. He completed a postdoctoral fellowship from Washington University in the Drosophila Genome project and a postdoctoral fellowship at Monsanto Corporation.
Dr. Edward J. Weinstein was co-Founder and President of SAGE Labs, a life science contract research organization with a focus on genetic engineering until it was acquired by Horizon Discovery in 2014. Edward continued at Horizon as President of the Research Services business unit until 2016. Prior to those roles, Edward served as Manager of R&D and Director of Operations in the Research Biotechnology business unit of Sigma-Aldrich. He has also worked in the pharmaceutical industry, leading molecular profiling portfolios for both Merck and Pfizer. Dr. Weinstein has earned a Ph.D. in genetics from Harvard University, a Masters of Medical Science from Harvard Medical School and bachelor degrees in Chemistry and Cellular-Molecular Biology from the University of Michigan.
George E. Bers
Mr. Bers’ career spans 38 years in the Life Science Research and Clinical Diagnostics industries. His experience includes the development, commercialization and management of products and system solutions in the fields of immunology, cellular and molecular biology research, drug discovery and development, translational medicine and molecular diagnostics. He served in numerous executive and senior management positions before his retirement in 2014. Most recently, Mr. Bers served as SVP Affymetrix and EVP Panomics Inc. (acquired by Affymetrix in Dec 2008). Prior to Panomics, he held positions of President, Life Science Research Division and VP, Systems Biology Business Center at Beckman Coulter and VP Business Development at Nanogen. Earlier, he held positions of VP, Group Manager Clinical Diagnostics and VP, Group Manager Molecular BioSystems at Bio-Rad Laboratories. Mr. Bers received a BS from Duke University and an MS in Biochemistry from Georgetown University. He also is a graduate of the Stanford Business School Executive Management Program.